MicroRNA-21 over expression in umbilical cord blood hematopoietic stem progenitor cells by leukemia microvesicles

Farnaz Razmkhah1, Masoud Soleimani2, Sorayya Ghasemi3 and Sedigheh Amini Kafi-abad4

1Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
2Department of Hematology, Faculty of Medicine, Tarbiat Modares University, Tehran, Iran.
3Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.
4Department of Pathology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.

Abstract

Microvesicles are able to induce the cell of origin’s phenotype in a target cell. MicroRNA-21, as an oncomir, is up-regulated in almost all cancer types such as leukemia which results in cell proliferation. In this study, we examine the ability of leukemia microvesicles to induce proliferation in hematopoietic stem progenitor cells (HSPCs) via microRNA-21 dysregulation. Herein, leukemia microvesicles were isolated from HL-60 and NB-4 cell lines by ultracentrifugation, and then their protein content was measured. Normal HSPCs were isolated from umbilical cord blood samples by a CD-34 antibody. These cells were treated with 20 and 40 μg/mL leukemia microvesicles for 5 and 10 days, respectively. Cell count, CD-34 analysis, and a microRNA-21 gene expression assay were done at days 5 and 10. HSPCs showed a significant increase in both microRNA-21 gene expression and cell count after treating with leukemia microvesicles compared with the control group. CD-34 analysis as stemness proof did not show any difference among the studied groups. This data suggests that HSPC proliferation followed by microRNA-21 gene over expression can be another evidence of a leukemia-like phenotype induction in a healthy target cell by leukemia microvesicles.

Keywords: Leukemia, microvesicles, hematopoietic stem cells, microRNA-21.

Received: March 14, 2018; Accepted: July 23, 2018.

Introduction

Microvesicles, membrane-derived sacs, are shed from a variety of cell types including both normal and abnormal cells under physiological or pathological condition (D’Souza-Schorey et al., 2012). They promote communication between the cells and surrounding environments based on their cargo which depends on the cell of origin (Muralidharan-Chari et al., 2010). Microvesicles carry both mRNAs and microRNAs, which can be transferred between cells as genetic materials (Lee et al., 2012), and transform the target cell’s phenotype according to the cell of origin (Jang et al., 2004; Aliotta et al., 2007; Renzulli et al., 2010). As they originate from a tumor cell, they contain its molecular signatures and operate intercellular communication based on this information (Martins et al., 2013). So it seems likely that tumor cell microvesicles are able to change a healthy cell’s phenotype and induce some tumor signatures.

MicroRNA-21, a short non-coding RNA, is the only microRNA up-regulated in all human malignancies and is involved in tumorigenesis, progression and metastasis (Vollinia et al., 2006; Pan et al., 2010). Also, it shows higher expression in leukemic stem cells (LSCs) than in hematopoietic stem cells (HSCs) (Martianez Canales et al., 2017). This microRNA plays a pivotal role in tumor cell proliferation via different target genes, and cell cycle arrest and apoptosis occur while its expression is inhibited (Chan et al., 2005; Li et al., 2009; Yao et al., 2009).

Acute myeloid leukemia (AML) is defined by defects in the differentiation of hematopoietic stem and progenitor cells in the bone marrow, which transform a healthy HSC into a LSC (Aberger et al., 2017). One of the first modifications in a LSC is an uncontrolled cell cycle and higher rate of proliferation, resulting in the accumulation of mutations and therefore, the first step for leukemogenesis (Schnurch et al., 2012).
While normal and leukemic cells exist in the same microenvironment, leukemia microvesicles are probably able to perform a cross-talk between cells and affect them. In this study, using leukemia microvesicles, we report alterations in the proliferation and microRNA-21 gene expression in healthy HSPCs as two important signatures of leukemia.

Material and Methods

Cell preparation

Leukemia cell lines (HL-60 and NB-4) were cultured in RPMI 1640 medium containing 20% fetal bovine serum (FBS) (for HL-60 cell line) and 10% FBS (for NB-4 cell line), 100 U/mL Penicillin and 100 µg/mL Streptomycin at 37 °C, 5% CO₂ and at least 90% humidity to obtain enough cells for microvesicles isolation.

Microvesicle isolation and characterization

Once enough cells were obtained, they were maintained (separately) in RPMI 1640 medium containing 0.6% bovine serum albumin (BSA), 100 U/mL Penicillin and 100 µg/mL Streptomycin at 37 °C, 5% CO₂ and at least 90% humidity overnight. The day after, cells supernatant was collected for microvesicle isolation and purification by ultra-centrifugation (Razmkhah et al., 2015). Briefly, the cell supernatant was centrifuged stepwise at 2000, 10,000 and 20,000xg to exclude cells (live and dead), cell debris and exosomes respectively. The final centrifugation at 20,000 x g was repeated to achieve a pure microvesicle pellet. Quality of isolated microvesicles was assessed by transmission electron microscopy (TEM) using negative staining by 2% uranyl acetate for 30s. A Bradford assay was done to measure the microvesicles’ protein concentration, and then they were used freshly to treat sorted HSPCs.

HSPC sorting

Umbilical cord blood samples collected in CPDA1 reagent from healthy donors were received from the Iranian Blood Transfusion Organization (IBTO) cord blood bank after written consent was obtained. Mononuclear cells (MNCs) were isolated by Lymphoprep (Stemcell Technologies, Vancouver, Canada) and then used to sort HSPCs by CD-34 magnetic immunobeads (Milteny Biotec, Auburn, CA) according to the manufacturer’s instructions.

Treating HSPCs with leukemia microvesicles

Sorted HSPCs were divided into 5 groups (55,000 cells in each group) for treatment: 1- without any microvesicles (as control group), 2- with 20 and 40 µg/mL HL-60 microvesicles (as H-20 and H-40 groups), 3- with 20 and 40 µg/mL NB-4 microvesicles (as N-20 and N-40 groups). The cells were kept in 500 µL Stemline medium (Sigma-Aldrich, St Louis, MO) containing 50 ng/mL of Thrombopoietin (TPO; PeproTech, London, UK) and Fms-like tyrosine kinase 3 (FLT3; ORF Genetics, Kopavogur, Iceland) recombinant growth factors for 5 and 10 days. HSPCs were treated with leukemia microvesicles only once at day 0. No more microvesicle were added later.

Cell count

After washing cells in phosphate-buffered saline (PBS) and staining them with Trypan Blue, viable cells were counted in a hemocytometer at days 5 and 10.

CD-34 analysis

Washed cells were stained by CD-34 antibody (PE-eBioscience, USA) to evaluate this HSPC specific marker at day 0 as purity index, and at days 5 and 10 as stemness marker.

microRNA-21 gene expression

Washed cells (without any microvesicles) were used for total RNA extraction by RNX Plus reagent (CinnaGen, Iran). Complementary DNAs (cDNAs) for microRNA-21 and Snord47 were then specifically synthesized according to the manufacturer’s instructions (ThermoFisher Scientific, Waltham, MA USA) using stem loop primers (Mohammadi-Yeganeh et al., 2013), as shown in Table 1. Quantitative real-time polymerase chain reaction (PCR) was performed to evaluate microRNA-21 gene expression fold change in an Applied Biosystems StepOne real-time system (Applied Biosystems, Foster City, CA, USA) using SYBR Green PCR master mix (TaKaRa, Japan) and specific primers (Table 1). The raw reads were normalized with Snord 47 and relative expression was calculated according to ΔΔCt method.

Statistical analysis

Results from three different experiments were statistically analyzed using SPSS 22 (Microsoft, Chicago, IL, Illinois).
USA). One way ANOVA was applied for comparing means among groups, and Tukey tests were done to find significant different between groups. Pearson’s test was applied to assay any correlation between the studied variables. An adjusted significance level less than 0.05 was considered statistically significant.

**Results**

**Microvesicle quality control**

Isolated microvesicles were qualitatively assessed by TEM as proof of the isolation protocol by showing the expected size of microvesicles (Figure 1). Also, the integrity of the microvesicles’ membrane was completely maintained during the different stages of isolation as shown in Figure 1. Hence, these microvesicles are suitable for treating healthy HSPCs.

**Cell proliferation**

HSPCs were counted after being treated with different amounts of microvesicles originated from the HL-60 and NB-4 lines. A significant increase in HSPCs number was observed after treatment with 20 and 40 μg/mL HL-60 and NB-4 microvesicles \(p<0.001\) compared with the respective control groups at days 5 and 10 (Figures 2 and 3). In addition, the cell count in the control groups decreased during these 10 days. No change in the morphology of HSPCs was observed at the different time points.

**HSPC marker**

A CD34 antigen assay as HSPC-specific marker and stemness marker was performed using flow cytometry (Figure 4) which showed a high level in HSPCs after treatment with 20 and 40 μg/mL HL-60 and NB-4 microvesicles compared to control groups at day 0 (Figure 5).

**microRNA-21 gene expression**

Quantitative Real Time PCR data revealed a significant overexpression of microRNA-21 gene in HSPCs after treatment with 20 and 40 μg/mL HL-60 and NB-4 microvesicles \(p<0.001\) compared with control groups at day 10 (Figure 6). No significant difference in microRNA-21 gene expression was observed among groups at day 5.

**Correlation test**

The Spearman test showed a strong correlation between cell count and microRNA-21 gene expression in HSPCs treated with 20 and 40 μg/mL HL-60 microvesicles at day 5 (correlation coefficient = 0.742, \(p=0.02\)) and day 10 (correlation coefficient= 0.965, \(p<0.001\)). Also, a positive correlation was observed between cell count and

![Figure 1 - Transmission electron microscopy image of isolated microvesicles. The maximum size of microvesicles is 1 μm in diameter. No damage is observed in microvesicles’ membrane.](image)

![Figure 2 - HSPC counts. A) HSPC counts after treatment with 20 and 40 μg/mL HL-60 microvesicles. B) HSPC counts after treatment with 20 and 40 μg/mL NB-4 microvesicles. (H: HL-60 microvesicles, N: NB-4 microvesicles) ** \(p<0.001\).](image)
Figure 3 - Increased number of HSPCs after treatment with leukemia microvesicles (400X). A) HSPCs at day 5. B) HSPCs at day 10.

Figure 4 - CD34 analysis. A) HSPCs gate. B) Isotype control (red histogram) and CD-34 positive cells (blue histogram).

Figure 5 - HSPC CD34 antigen assay (percentage). A) After treatment with 20 and 40 μg/mL HL-60 microvesicles. B) After treatment with 20 and 40 μg/mL NB-4 microvesicles.
MicroRNA-21 gene expression in HSPCs treated with 20 and 40 µg/mL NB-4 microvesicles at day 5 (correlation coefficient= 0.854, p = 0.003) and day 10 (correlation coefficient= 0.962, p<0.001).

Discussion

Microvesicles are important transporters of genetic information and play a key role in disease spread by tumor cell/normal cell interactions (Baj-Krzyworzeka et al., 2006; Martins et al., 2013; Fujita et al., 2016). This paracrine signaling is common in a tumor microenvironment where tumor and normal cells are close to each other. Also, tumor cells can adopt an aggressive phenotype, a result of their interaction with other tumor cells via microvesicles (Al-Nedawi et al., 2008).

In this study, we designed an experiment with a small community of leukemia microvesicles and healthy HSPCs to show interactions that indicate transformation of HSPCs as a target cell type. HL-60 and NB-4 cell lines were selected for this study, both of which belong to M3 subtype of AML, one without translocation (HL-60) and the other with translocation t(15;17)(NB-4). Leukemia microvesicles were isolated from them and were used to treat healthy HSPCs at doses of 20 and 40 µg/mL for 5 days and 10 days. As an important point, we did not use SCF growth factor in the HSPCs culture media to avoid and eliminate its proliferation effect. Although this resulted in cell death and count decrease in control groups (groups without microvesicles), it helped us to explore the role of leukemia microvesicles in the cell proliferation of the other groups (groups with microvesicles). Surprisingly, higher numbers of HSPCs were observed in the different experimental groups than in their control groups.

We previously reported that 30 µg/mL leukemic bone marrow derived microvesicles (non-M3 subtypes of AML) permit the survival of healthy HSPCs until day 7 compared with control groups (Razmkhah et al., 2017). We also showed that 20 µg/mL microvesicles from the Jurkat cell line (T-ALL) induce survival in healthy HSPC until day 7 (Razmkhah et al., 2015). The current study also showed that M3 microvesicles can induce survival in healthy HSPCs, like non-M3 and T-ALL microvesicles, even until day 10. This finding is of interest as the low dose of leukemia microvesicles (20 and 30 µg/mL) promoted survival and the higher dose (40 µg/mL) stimulated proliferation in healthy HSPCs. Ghosh et al. (2010) showed that B cell chronic lymphoblastic leukemia (B-CLL) derived microvesicles are able to activate and sustain activated AKT signaling in bone marrow stromal cells to produce vascular endothelial growth factor (VEGF) as a survival factor for CLL B cells. Another study showed that chronic myeloblastic leukemia (CML) derived exosome (another extracellular vesicle with smaller size than microvesicles) can promote both survival and proliferation of CML cells through an autocrine mechanism by a ligand-receptor interaction between TGF-β1, found in CML-derived exosomes, and the TGF-β1 receptor on CML cells. (Raimondo et al., 2015) Moreover, Wang et al. (2016) found that LSC derived microvesicles prevent apoptosis and induce survival in AML cells associated with microRNA-34 deficit. Also, Skog et al. (2008) concluded that glioblastoma microvesicles stimulate proliferation of a human glioma cell. These studies indicate that tumor cell derived microvesicles can potentially change their environment to provide a better situation for survival and proliferation, or increase the survival of adjacent tumor cells for disease progression.

MicroRNA-21, an oncogenic microRNA, affects the expression of multiple tumor suppressor genes, such as Phosphatase and Tensin homolog (PTEN), Serpin1, and programmed cell death protein 4 (PDCD4), which results in cell growth and proliferation (Sekar et al., 2016). This microRNA is also up-regulated in numerous cancer stem cells (CSCs) (Sekar et al., 2016) such as LSCs, but not in healthy HSPCs (Martinez Canales et al., 2017). By inhibiting microRNA-21 in myeloid cell lines, such as HL60 and
K562, reduced cell growth, induced apoptosis and increased sensitivity to different chemotherapeutic agents were observed, providing support for the role of this microRNA in leukemia progression (Hu et al., 2010; Li et al., 2010; Bai et al., 2011; Gu et al., 2011). Medina and colleagues showed that miR-21 over-expression alone leads to a pre-B malignant lymphoid-like phenotype in a mouse model, which was regressed completely when microRNA-21 was inactivated (Medina et al., 2010). This is a clear evidence that microRNA-21 is able to uniquely transform a healthy HSPC to express a malignant phenotype. In the current study, we found about a 10 and 15 times increase in microRNA-21 gene expression in healthy HSPCs after treatment with 40 μg/mL leukemia microvesicles from HL-60 and NB-4 cell lines, respectively. This is directly correlated with cell count (p<0.001), which shows the expected role of microRNA-21 in cell survival and proliferation. After 10 days of culture, HSPCs still express more than 70% CD-34 antigen, which proves they are still stem cells. Hence, microRNA-21 over-expression and increased cell proliferation happened in a stem cell. This new stem cell with higher proliferation and microRNA-21 gene expression is now different from the control group.

In the bone marrow of patients with acute myeloid leukemia, leukemia cells occupy all the bone marrow microenvironment. But few healthy HSPCs still exist in the neighborhood of leukemia cells. As a rule, cancer cells produce huge amounts of microvesicles due to their high rate of proliferation (Ginestra et al., 1998). These microvesicles can now penetrate to an adjacent cell, which can be a healthy HSPC, and transform it by increasing microRNA-21 gene expression and promote high proliferation. This can also occur in an adjacent leukemia cell to induce more proliferation than before. In addition, once remission is achieved, LSCs that are resistant to current chemotherapies, still exist in the bone marrow and are able to proliferate and differentiate to leukemia blasts. These few leukemia cells now produce microvesicles and can affect adjacent healthy cells to express microRNA-21 gene, resulting in high proliferation and an increase in the speed of relapse.

Therefore, leukemia microvesicles in a leukemic microenvironment, wherein normal and malignant cells are close to each other, are potentially able to transfer some phenotypes of leukemia, such as high proliferation between cells and result in disease progression. Moreover, they can transform the genotype of target cells to express higher rate of an oncomir, microRNA-21, to have a continuous proliferation like a leukemia cell. So, this mechanism of disease progression should be inhibited by blocking microvesicle production in leukemia cells to clinically improve the chemotherapy results and decrease the rate of relapse.

In conclusion, we found relevant changes in a healthy HSPC after treatment with leukemia microvesicles, which promotes a leukemia-like phenotype and provides evidence of potential disease spread in a leukemic microenvironment.

**Acknowledgments**

This project was supported by Shiraz University of Medical Sciences. We would like to thank the Iranian Blood Transfusion Organization for providing cord blood samples.

**Conflict of interest**

All authors declare no conflict of interest.

**Author contributions**

FR and MS conceived and designed the study, FR conducted the experiments, analyzed the data and wrote the manuscript, FR, MS, SG and SAK discussed the data, SG critically reviewed the manuscript, SAK provided clinical samples, all authors read and approved the final version.

**References**


**Acknowledgments**

This project was supported by Shiraz University of Medical Sciences. We would like to thank the Iranian Blood Transfusion Organization for providing cord blood samples.

**Conflict of interest**

All authors declare no conflict of interest.

**Author contributions**

FR and MS conceived and designed the study, FR conducted the experiments, analyzed the data and wrote the manuscript, FR, MS, SG and SAK discussed the data, SG critically reviewed the manuscript, SAK provided clinical samples, all authors read and approved the final version.

**References**


**Acknowledgments**

This project was supported by Shiraz University of Medical Sciences. We would like to thank the Iranian Blood Transfusion Organization for providing cord blood samples.

**Conflict of interest**

All authors declare no conflict of interest.

**Author contributions**

FR and MS conceived and designed the study, FR conducted the experiments, analyzed the data and wrote the manuscript, FR, MS, SG and SAK discussed the data, SG critically reviewed the manuscript, SAK provided clinical samples, all authors read and approved the final version.

**References**


Associate Editor: Alysson Muotri

License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License (type CC-BY), which permits unrestricted use, distribution and reproduction in any medium, provided the original article is properly cited.